If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
They also reported that facilities that offered these surgeries were also posting about them on TikTok. TikTok has banned the advertising of cosmetic surgeries on the platform but cosmetic surgeons are still able to reach large audiences using unpaid photo and video posts. NBC reported that videos using the hashtags '#plasticsurgery' and '#lipfiller' had amassed a combined 26 billion views on the platform. In December 2022, it was reported that a cosmetic surgery procedure known as buccal fat removal was going viral on the platform. The procedure involves surgically removing fat from the cheeks in order to give the face a slimmer and more chiseled appearance. Videos using hashtags related to buccal fat removal had collectively amassed over 180 million views. Some TikTok users criticized the trend for promoting an unobtainable beauty standard.
The meta-analysis, which pooled published results of five large clinical trials, also found that the treatment cut the rate of breathing problems and reduced the need for placing a baby on a ventilator.
Antigen presentation is a vital immune process that is essential for T cell immune response triggering. Because T cells recognize only fragmented antigens displayed on cell surfaces, antigen processing must occur before the antigen fragment can be recognized by a T-cell receptor. Specifically, the fragment, bound to the major histocompatibility complex (MHC), is transported to the surface of the antigen-presenting cell, a process known as presentation. If there has been an infection with viruses or bacteria, the antigen-presenting cell will present an endogenous or exogenous peptide fragment derived from the antigen by MHC molecules. There are two types of MHC molecules which differ in the behaviour of the antigens: MHC class I molecules (MHC-I) bind peptides from the cell cytosol, while peptides generated in the endocytic vesicles after internalisation are bound to MHC class II (MHC-II). Cellular membranes separate these two cellular environments - intracellular and extracellular. Each T cell can only recognize tens to hundreds of copies of a unique sequence of a single peptide among thousands of other peptides presented on the same cell, because an MHC molecule in one cell can bind to quite a large range of peptides. Predicting which (fragments of) antigens will be presented to the immune system by a certain MHC/HLA type is difficult, but the technology involved is improving.
=== Acetylcholine === Acetylcholine is required for the generation of muscular force. In the central nervous system, acetylcholine modulates arousal and temperature regulation. It also may play a role in central fatigue. During exercise, levels of acetylcholine drop. This is due to a decrease in plasma choline levels. However, there have been conflicting results in studies about the effect of acetylcholine on fatigue. One study found that plasma choline levels had dropped 40% after the subjects ran the Boston Marathon. Another study found that choline supplementation did not improve time to exhaustion. This study also found that plasma choline levels had not changed in either the placebo or the choline supplemented groups. More research is needed to investigate acetylcholine's effects on fatigue.
Hereditary coproporphyria (HCP) is a disorder of heme biosynthesis, classified as an acute hepatic porphyria. HCP is caused by a deficiency of the enzyme coproporphyrinogen oxidase, coded for by the CPOX gene, and is inherited in an autosomal dominant fashion, although homozygous individuals have been identified. Unlike acute intermittent porphyria, individuals with HCP can present with cutaneous findings similar to those found in porphyria cutanea tarda in addition to the acute attacks of abdominal pain, vomiting and neurological dysfunction characteristic of acute porphyrias. Like other porphyrias, attacks of HCP can be induced by certain drugs, environmental stressors or diet changes. Biochemical and molecular testing can be used to narrow down the diagnosis of a porphyria and identify the specific genetic defect. Overall, porphyrias are rare diseases. The combined incidence for all forms of the disease has been estimated at 1:20,000. The exact incidence of HCP is difficult to determine, due to its reduced penetrance.
Sources: en.wikipedia.org
==== Nemaline myopathy ==== Nemaline myopathy was first described in 1963 and is the most common congenital myopathy. It is characterized by generalized muscle weakness and low muscle tone. In its severest form, affected babies often die from respiratory failure. To date, 9 gene mutations have been found to cause nemaline myopathy. 6 of the identified genes are associated with the actin filament, which is the basis for muscle contraction. Histologically, nemaline rods stain red with Gomori's trichrome and are mostly seen in the subsarcolemmal region of muscle fibres. Nemaline rods have also been observed in the intermyofibrillar region of muscle fibres and within the nucleus. Nemaline myopathy is an autosomal dominant and sometimes an autosomal recessive genetic disorder. Sporadic cases have also been described.
7 and Transitional Provisions) Order 1993 (S.I. 1993/2229) National Assistance (Assessment of Resources) (Amendment No.2) Regulations 1993 (S.I. 1993/2230) National Curriculum Council and School Examinations and Assessment Council (Designation of Staff) Order 1993 (S.I. 1993/2231) Export of Goods (Control) (Haiti) (Revocation) Order 1993 (S.I. 1993/2232) Motor Vehicles (Competitions and Trials) (Amendment) Regulations 1993 (S.I. 1993/2233) Road Traffic (Special Parking Areas) (London Boroughs of Bromley, Hammersmith and Fulham and Lewisham) (London Borough of Wandsworth) (Amendment) Order 1993 (S.I. 1993/2237) Housing (Extension of Right to Buy) Order 1993 (S.I. 1993/2240) Housing (Preservation of Right to Buy) Regulations 1993 (S.I. 1993/2241) Valuation Timetable (Scotland) Amendment (No.3) Order 1993 (S.I. 1993/2242) Housing (Right to Buy Delay Procedure) (Prescribed Forms) (Amendment) Regulations 1993 (S.I. 1993/2245) Housing (Right to Buy) (Prescribed Forms) (Amendment) Regulations 1993 (S.I. 1993/2246) Law Reform (Miscellaneous Provisions) (Scotland) Act 1990 (Commencement No.12) Order 1993 (S.I. 1993/2253) Public Trusts (Reorganisation) (Scotland) (No.2) Regulations 1993 (S.I. 1993/2254) Fish Health (Amendment) Regulations 1993 (S.I. 1993/2255) Royal National Hospital for Rheumatic Diseases National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2256) St Peter's Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I.
A vent site in the Cayman Trough named Beebe, which is the world's deepest known hydrothermal site at ~5,000 m (16,000 ft) below sea level, has shown sustained supercritical venting at 401 °C (754 °F) and 2.3 wt% NaCl. Although supercritical conditions have been observed at several sites, it is not yet known what significance, if any, supercritical venting has in terms of hydrothermal circulation, mineral deposit formation, geochemical fluxes or biological activity. The initial stages of a vent chimney begin with the deposition of the mineral anhydrite. Sulfides of copper, iron, and zinc then precipitate in the chimney gaps, making it less porous over the course of time. Vent growths on the order of 30 cm (1 ft) per day have been recorded. An April 2007 exploration of the deep-sea vents off the coast of Fiji found those vents to be a significant source of dissolved iron (see iron cycle).
The Raleigh area has hosted the Professional Golfers' Association (PGA) Nationwide Tour Rex Hospital Open since 1994, with the current location of play at Raleigh's Country Club at Wakefield Plantation. Nearby Prestonwood Country Club hosts the PGA SAS Championship every fall.
Sources: en.wikipedia.org
== External links == "Burkholderia pseudomallei genomes and related information". PATRIC. NIAID. Archived from the original on 2011-08-24. Retrieved 2010-06-24. "Getting a Grip on the Great Mimicker: Secrets of a Stealth Organism". Wellcome Trust. Archived from the original on 2009-09-27. Retrieved 2006-03-27. Pathema Burkholderia resource "Burkholderia pseudomallei". NCBI Taxonomy Browser. 28450.
=== Inhibin === In both females and males, inhibin inhibits FSH production. Inhibin does not inhibit the secretion of GnRH from the hypothalamus. However, the overall mechanism differs between the sexes:
==== Combination formulations ==== Adapalene/benzoyl peroxide (CD-0271/CD-1579; Epiduo; GK-530G; Tactuo; TactuPump) – combination of adapalene (retinoid) and benzoyl peroxide (undefined mechanism of action) Adapalene/benzoyl peroxide/clindamycin phosphate (Cabtreo; IDP-126) – combination of adapalene (retinoid), benzoyl peroxide (undefined mechanism of action), and clindamycin phosphate (lincosamide antibiotic) Benzoyl peroxide/clindamycin (Duac) – combination of benzoyl peroxide (undefined mechanism of action) and clindamycin (lincosamide antibiotic) Benzoyl peroxide/clindamycin low dose (Acanya; BenzaClin; Clin-BPO; Onexton) – combination of benzoyl peroxide (undefined mechanism of action) and clindamycin (lincosamide antibiotic) Benzoyl peroxide/tretinoin – combination of benzoyl peroxide (undefined mechanism of action) and tretinoin (retinoid) Clindamycin/tretinoin (Acnatac; Acnex; CLin-RA; Ziana) – combination of clindamycin (lincosamide antibiotic) and tretinoin (retinoid) Ethinylestradiol/drospirenone low-dose (Yasmin, Yaz) – combination of ethinylestradiol (estrogen) and drospirenone (progestogen) and a combined oral contraceptive Ethinylestradiol/drospirenone/levomefolic acid (BAY98-7071; Beyaz; Safyral; Yasmin Plus; Yaz Flex Plus; Yaz Plus) – combination of ethinylestradiol (estrogen), drospirenone (progestogen), and levomefolic acid (vitamin B9) and a combined oral contraceptive
=== Safety === In the 1990s, several reports reviewed the few studies evaluating any increased risk of systemic and auto-immune diseases among women with breast implants. The conclusion at that time was that there was no evidence establishing a causal connection between the implantation of silicone breast implants and either type of disease. However, the Institute of Medicine report pointed out that these earlier studies included too few women to conclusively evaluate the impact on these rare diseases. In addition, many of the studies included women who had breast implants for just a few months, which would be too early to develop a diagnosed autoimmune disease. In recent years, large epidemiological studies have reported clinically and statistically significant increases in some of these diseases. A study by Watad and colleagues that was published in 2018 compared and examined the medical records of more than 24,000 women with breast implants to more than 98,000 "matched controls" who did not have breast implants but shared very similar demographic traits. The study found a statistically significant 22% overall increase in diagnosed autoimmune or rheumatic disorders. The greatest increases in diagnoses for women with breast implants was for Sjögren's syndrome, Multiple Sclerosis (MS), and sarcoidosis, each of which were 58%-98% higher in women with breast implants.
== Properties of the imidazole side chain == At neutral or physiological pH, the imidazole side chain is neutral. The imidazole side chain in histidine has a pKa of approximately 6.0. Thus, below a pH of 6, the imidazole ring is mostly protonated and carries a positive +1 charge (as described by the Henderson–Hasselbalch equation). The resulting imidazolium ring bears two NH bonds and has a positive charge. The positive charge is equally distributed between both nitrogen atoms and can be represented with two equally important resonance structures. Sometimes, the symbol Hip is used for this protonated form instead of the usual His. Above pH 6, one of the two protons is lost. The remaining proton of the imidazole ring can reside on either nitrogen atom, giving rise to what are known as the N3-H or N1-H tautomers. In the N1-H tautomer, the NH group is nearer the backbone. These neutral tautomers, also referred to as Nε (or Nτ, tau meaning tele — far) and Nδ (or Nπ, pi meaning pros — near), are sometimes referred to with symbols Hie and Hid, respectively. The imidazole/imidazolium ring of histidine is aromatic at all pH values. Under certain conditions, all three ion-forming groups of histidine can be charged forming the histidinium cation. The acid-base properties of the imidazole side chain are relevant to the catalytic mechanism of many enzymes. In catalytic triads, the basic nitrogen of histidine abstracts a proton from serine, threonine, or cysteine to activate it as a nucleophile. In a histidine proton shuttle, histidine is used to quickly shuttle protons.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.